^
Association details:
| Biomarker: | HER-2 overexpression |
|---|---|
| Cancer: | Gastric Adenocarcinoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + Herceptin (trastuzumab) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
08/03/2021
Excerpt:
Gastric cancer: First-line therapy…other recommended regimens…HER2 overexpression positive adenocarcinoma…Fluoropyrimidine (fluorouracil or capecitabine) and cisplatin and trastuzumab and pembrolizumab…Fluoropyrimidine (fluorouracil or capecitabine) and oxaliplatin and trastuzumab and pembrolizumab
Secondary therapy:
capecitabine + oxaliplatin; cisplatin + 5-fluorouracil; 5-fluorouracil + oxaliplatin; cisplatin + capecitabine
